retatrutide
5 articles tagged with ‘retatrutide’
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
GLP-1 Receptor Agonist Peptides: A 2026 Research Landscape
An overview of the GLP-1 receptor agonist research landscape in 2026, covering semaglutide, tirzepatide, retatrutide, and emerging dual- and triple-agonist peptides.
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.
Retatrutide (RETA) Research: Triple Agonist Metabolic Effects
Retatrutide, known online as RETA, acts as a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon pathways in metabolic research. Phase 2 trial data showed up to 17.5% mean body weight reduction at 24 weeks and 24.2% at 48 weeks in the highest-dose group. Studies explore its effects on appetite, glucose control, energy balance, liver fat, and neurological pathways beyond just weight loss.